Dr. Frederick Feit named Master Clinician at Dean's Honors Day

Master Clinician Frederick Feit, MD
Associate Professor of Medicine

Internationally recognized for his scientific contributions and technical expertise, Dr. Feit revolutionized the treatment of patients with coronary artery disease. In collaboration with Dr. K. Peter Rentrop, he pioneered the injection of streptokinase directly into coronary arteries of patients having myocardial infarctions. He demonstrated that injecting thrombolytic agents during cardiac catheterization of an artery totally obstructed by a thrombus could promptly restore blood flow to the heart, stop the loss of heart muscle, and limit the size of, and disability from, a heart attack.

The results of this seminal work were published in the New England Journal of Medicine and changed the way medicine was practiced. Today, whenever a patient presents with a heart attack, he or she is immediately rushed to a catheterization lab to have the obstructed coronary artery opened.

Dr. Feit has been the principal investigator on numerous NIH- sponsored clinical trials involving patients with coronary artery disease and diabetes mellitus. While principal investigator of the Bypass Angioplasty Revascularization Investigation (BARI), he authored an insightful comparison of the randomized trial and parallel registry. This analysis, published in Circulation, compared the outcomes of patients with multivessel coronary artery disease undergoing bypass surgery with those undergoing balloon angioplasty. The results showed that among patients with diabetes mellitus, physician-guided individualization of care allowed the use of the less invasive therapy (coronary angioplasty) rather than bypass surgery, without compromising long-term outcomes.

He also served as head of the steering committee for the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, an international trial that assessed the optimal antiplatelet and antithrombin regimen for patients presenting with acute coronary syndromes. The results of this trial, which included 14,000 patients, confirmed his hypothesis that patients with unstable presentations from coronary artery disease are most expeditiously and safely treated with simple antithrombotic regimens rather than the more complex regimens that had been the standard of care. Dr. Feit was the first to show in an active, controlled trial, that in patients undergoing coronary artery stenting, periprocedural bleeding complications were an independent predictor of long-term mortality. The results of the ACUITY trial left few, if any, doubters of the importance of preventing bleeding complications.

Author of hundreds of scientific papers, reviews, chapters, and abstracts in all of the major medical and cardiology journals, for which he has also served as a reviewer, Dr. Feit has shared his insights regarding clinical trials, novel procedural techniques, and pharmacologic approaches to optimize clinical outcomes in presentations, lectures, and debates all over the world.

An associate professor of medicine and director of the fellowship program in interventional cardiology, Dr. Feit has trained more than 100 fellows in the practice of interventional cardiology and has reminded thousands of medical students and residents of his belief that you must treat every patient as your only patient.

In addition to his clinical work and research, Dr. Feit hosts "Heart to Heart," a program on Doctor Radio.

Dr. Feit completed his undergraduate and medical education at NYU. He earned membership in both Phi Beta Kappa and Alpha Omega Alpha and served his internship, residency, chief residency, and cardiology fellowship at Bellevue and NYU Langone. Prior to his current roles, he directed the catheterization laboratories at both Bellevue and Tisch Hospitals and introduced coronary angioplasty at Bellevue, the Manhattan and Brooklyn VAs, and Downstate Hospitals.